. 2012 Dec 7;207(5):740–748. doi: 10.1093/infdis/jis750

Table 4.

Summary of Subjects Demonstrating Integrase Genotype Evolution, Reduction in Dolutegravir (DTG) Susceptibility, or Both on Day 11^a

Subject	Integrase Mutational Group	Change in HIV-1 RNA From Baseline, log₁₀ Copies/mL	PSS of Failing Regimen on Day 1	RAL Resistance–Associated Mutations^b		DTG FC
Subject	Integrase Mutational Group	Change in HIV-1 RNA From Baseline, log₁₀ Copies/mL	PSS of Failing Regimen on Day 1	Day 1	Day 11	Day 1	Day 11
Cohort I
S1	Y143	−1.61	1	L74M, T97A, Y143R, G163G/R	L74L/M, T97A, E138E/K, Y143Y/ R/H/C, G163G/R	1.03	1.09
S2	Mixture	−0.32	1	G140S, Y143H, Q148H	L74I/M, E138E/A, G140S, Q148H	6.49	38
Cohort II
S3	Q148 + 2	−1.79	0	E138E/K, G140G/S, Q148Q/H	T97T/A, E138E/K, G140S, Q148H	2.1	11
S4	Q148 + 1	−1.57	0	G140S, Q148H	G140S, Q148H, N155N/H	6.23	NR
S5	Q148 + 2	−0.9	0	E138A, G140S, Q148H	T97T/A, E138T/A, G140S, Q148H	6.04	21

Abbreviations: FC, fold-change in 50% inhibitory concentration; NR, no results; PSS, phenotypic susceptibility score; RAL, raltegravir.

^a In subjects with paired day 1 and day 11 integrase genotype and phenotype.

^b Differences in integrase genotype between day 1 and day 11 are bold.